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Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not 
Triptan drugs are safe and effective for use in the prevention of menstrually related 
migraines (MRMs).   
 
Study Design: Review of two English language randomized controlled trials and one 
pilot randomized control trial 
 
Data Sources: Randomized controlled trials comparing Triptan drugs to a placebo group 
were found using Medline, PubMed, and OVID 
 
Outcomes Measured: Incidence of MRM based on patient self-report; number of 
relapses; patients’ subjective evaluations of effectiveness based on questionnaire; adverse 
effects of Triptan treatment 
 
Results: Two randomized controlled trials and one pilot study were included in this 
review.  Oral Triptan drugs were shown to be of benefit in the prevention of menstrually 
related migraines (MRMs). 
 
Conclusions: The results of the randomized controlled trials reviewed demonstrate that 
oral Triptan drugs, given short-term, were safe and effective at preventing menstrually 
related migraines (MRMs).  However, in one of the RCTs, some migraineurs experienced 
post-treatment attacks.  There is not a clear explanation for these post-treatment attacks; 
further studies need to be conducted to allow for more flexible dosing in order to ensure 
that the migraineurs are being treated during their perimenstrual period (PMP).  
Additionally, further studies should be conducted comparing Triptan dosing schedules, 
dosages, duration of treatment, routes of administration as well as the efficacy of the 
drugs within the Triptan class in preventing MRMs.  
 
Key Words: migraine, Triptan, menstruation 
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Introduction 
Menstrually related migraine (MRM) is a common disorder among women 
migraineurs.  Approximately 60% of women with migraines report an increase in frequency 
and/or severity of migraine attacks around the time of their menstrual period.2  The generally 
accepted definition of a menstrually related migraine is a migraine that occurs during the 
perimenstural period (PMP), which is equated to two days before menses through 2-4 days 
of menstruation.2  In MRMs, attacks may occur at other times of the cycle.  Attacks that 
occur exclusively with menses are reported in 15% of female migraine patients.1  According 
to the International Headache Society (IHS), the criteria for diagnosing a menstrual migraine 
is that it must occur on days -2 to +3 of menstruation in at least two of three consecutive 
cycles.  
MRMs are similar to migraine without aura but MRMs tend to be longer in duration, 
more intense in severity, less responsive to treatment, and more subject to recurrence after 
initial treatment.2  The symptoms of MRMs occur two days before onset of menstruation to 
2-4 days during menstruation and are unilateral in location, pulsatile in quality, moderate to 
severe in intensity, made worse by physical activity, and associated with nausea, 
photophobia, and phonophobia.3   
The exact pathophysiology of MRMs is not understood but it is of the general belief 
that they are related to the decrease in estrogen levels at menstruation.  The trigger of the 
MRMs may be related to either the level of estrogen before decline, the rate of decline, or 
the magnitude of decline.1  
Although there is no recent data, in 2003 there were 10.4 million US physician office 
visits for headache.4  “More than 50% of migraine sufferers report a clear relationship 
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between migraine attacks and menstrual flow and 10% of patients show migraine 
symptomatology exclusively during the PMP.”3 Medical costs of patients with migraine are 
estimated to be $2,571/person/year higher than in non-migraine patients.4  The direct cost of 
migraine management in the United States is estimated to be $17.7 billion dollars every 
year; of this, $1.3 billion represents migraine medical care and $16.5 billion represents 
medical costs related to lost of productivity.4  To equate these costs to the percentage of 
migraineurs who suffer MRMs, it is estimated that between $1.7 and $8.85 billion is spent 
on MRM management.  Of this, it is estimated that between 130 million and 650 million 
dollars is spent on direct medical care and between 1.65 and 8.25 billion dollars is spent on 
loss of productivity due to MRMs.   
Three pharmacologic approaches exist for the treatment of MRMs.  Short-term 
therapy is directed at decreasing both the length and severity of individual migraine attacks.  
Long-term preventative therapy taken daily without reference to menstruation is directed at 
decreasing attack frequency and severity.  Short term preventative therapy is intended to 
take before the onset of monthly menstruation.1  Pharmacologic options for MRM 
prophylaxis include NSAIDS, ergotamine, dihydroergotamine (DHE), methysergide, 
magnesium, beta blockers and calcium channel blockers.  Triptans are not only one of the 
most frequently used medications in the treatment of acute migraines, but also are the most 
effective treatment option.  The indication of Triptans for the prevention of MRMs remains 
to be seen. 
Objective 
The objective of this selective EBM review is to determine whether or not Triptan 
drugs are safe and effective for use in the prevention of menstrually related migraines 
(MRMs). 
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Methods 
Specific criteria was designated for the selection of the three trials used in this paper.  
Criteria for population included women migraineurs aged > 18 years old with MRMs.  
Menstrually related migraines were defined as migraines that occur in at least two of three 
consecutive cycles on days -2 to +3 of menstruation.  The intervention used was 
prophylactic oral Triptan drugs.  The treatment group receiving a Triptan drug was 
compared to the control group receiving a visually matched placebo.  Outcomes measured 
included the incidence of MRMs based on self-report, number of relapses, patients’ 
subjective evaluations of effectiveness based on questionnaire, and adverse effects of 
Triptan treatment.  The types of studies included two RCT (randomized controlled trials) 
and a pilot randomized controlled trial. 
In Silberstein’s study, patients treated each of their three perimenstrual periods 
(PMP) with placebo, Frovatriptan 2.5 mg QD, or Frovatriptan 2.5 mg BID for six days, 
beginning two days before anticipated start of MRM.  The primary outcome that was 
measured in this study was the incidence of HA during these six days.1   The results of this 
study were presented as two different subsets of populations.  The “ITT” group represented 
those patients who took their medication for at least one PMP (perimenstrual period).  The 
“ITT2” group represented those patients who took all three doses for all three PMPs. 
 Mannix’s study was comprised of two identically designed, randomized double-blind 
parallel group studies.  Women received Naratriptan 1 mg BID or a placebo; they took the 
study medication three days before their predicted MRM for a total of six days and repeated 
this for four consecutive menstrual cycles.2  The primary outcome measured in this study 
endpoint was the mean percentage of treated PMPs without MRM, as per patient report.  
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Secondary outcomes measured were the percentage of patients who were free of MRM 
during all treated PMPs and patient satisfaction.  To determine safety of Naratriptan, adverse 
events, laboratory tests and vital signs were recorded and analyzed.2   
Facchinetti’s study evaluated patients over two menstrual cycles.  The patients 
received Sumatriptan suppositories (25 mg) to treat attacks in the first cycle and oral 
Sumatriptan tablets (50 mg) to treat all attacks in the second cycle.3  The primary outcome 
measured was pain relief two hours post-administration. Secondary outcomes of interest in 
this study were the number of relapses as well as patients’ appraisal of the study medication 
after each treatment period, according to a verbal scale: “ineffective”, “moderately good”, 
“good”, “excellent.”3 
Data Sources 
Keywords used in literature search were “migraine”, “Triptan”, and 
“menstruation”. All articles were published in peer reviewed journals in the English 
language.  Literature searches were conducted via Medline, Pubmed, and OVID.  Articles 
were selected based on their relevance and on the importance of outcomes to the patient -- 
patient oriented evidence that matters (POEMS).  Studies included in the search were 
randomized, placebo-controlled, double-blind studies.  Studies that were excluded were 
those with a patient population under the age of 18 and with a patient population that 
included males.  Statistics reported in these studies included RRR (relative risk reduction), 
ARR (absolute risk reduction), NNT (numbers needed to treat), and p-values.   
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Table 1- Demographics and Characteristics of included studies 
Outcomes Measured  
Outcomes measured were those of patient oriented evidence that matters (POEMs).  
Incidence of MRMs was reported via self-report.  Patient’s subjective evaluations of overall 
effectiveness were measured via questionnaires: “poor”, “fair”, “good”, or “excellent” 
(Silberstein); “very” to “somewhat” satisfied, “neutral”, “very” to “somewhat” dissatisfied 
(Mannix); “ineffective”, “moderately good”, “good”, “excellent” (Facchinetti).1,2,3  Adverse 
events were  measured based on patient report.  
 
STUDY TYPE # PTS AGE INCLUSION CRITERIA EXCLUSION 
CRITERIA 
W/D INTERVENTIONS 
 
 
 
 
Silberstein1, 2004 
 
Randomized, 
double-blind, 
placebo-
controlled trial 
 
 
 
 
546 
 
 
18-56 
 
Mean age = 
37.6 
 
 
Women migraineurs aged > 
18 years with: 
migraine headaches 
according to IHS criteria 
>3 non-MRM attacks 
per month 
<15 headache days per 
month 
treated with other 
investigational drugs, 
Pregnant and breast-
feeding patients 
 
 
 
103 
 
 
Frovatriptan 2.5 mg QD 
and Frovatriptan 2.5 mg 
BID (both for 6 days) 
 
 
 
 
 
Mannix2, 2007. 
 
 
2 identical, 
randomized, 
double-blind, 
placebo-
controlled, 
parallel-group 
studies 
 
 
 
Study 1: 
287 
 
Study 2: 
346 
Study 1: 
36.1 
(triptan); 
37.7 
(placebo) 
 
Study 2: 
36.7 
(triptan), 
36.3 
(placebo) 
 
 
 
At least 18 years of age; 1 
yr H/O migraine as defined 
by IHS criteria 
 
 
More than 6 migraines 
monthly during either 
of the 2 months before 
screening;  
Pregnant or 
breastfeeding 
 
 
 
20% 
study 1  
& 10% 
study 2 
 
 
 
Naratriptan 1 mg BID 
for 4 PMPs  
 
 
 
 
Facchinetti3, 
2010 
 
 
 
 
 
 
pilot study 
 
 
 
 
 
71 
 
 
 
 
 
22-48 (avg 
35.3 +/- 7.5) 
2 groups of women 
suffering from migraine 
without aura, age range 18-
50, diagnosed according to 
the criteria in IHS, 
First group: women 
suffering from MRM 
Second group: women 
suffering from OCMM (oral 
contraceptive menstrual 
migraine) 
 
 
 
Patients on 
prophylactic 
medication to prevent 
migraine; patients 
taking oral 
contraceptive for < 3 
months 
 
 
 
 
 
8 
 
 
Sumatriptan 
suppositories (25 mg) for 
all migraine attacks in 
the first cycle & 
Sumatriptan tablets 
(50mg) for all attacks in 
the second cycle. 
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Results 
In Silberstein’s ITT group, Frovatriptan 2.5 mg QD and 2.5 mg BID were both 
superior to placebo in reducing incidence of MRMs.   The incidence of MRM with placebo 
was 67% (n=325).1  This percentage was reduced to 52% (n=251; p<0.0001) with use of 
Frovatriptan 2.4 mg QD and 41% (n=199; p<0.0001) with use of Frovatriptan 2.5 mg BID.1  
In ITT2, the percentage of patients with an incidence of MRM was 69% (n=307), 52% 
(n=232; p<0.0001), and 43% (n=190; p<0.0001), respectively.1  For both ITT and ITT2, the 
QD dosed group represents the experimental event rate (EER) and the placebo dosed group 
represents the control event rate (CER).   
Both the QD and BID doses reduced the incidence of migraines more effectively 
when compared to placebo (p<0.0001).  However, the BID dose was rated as more effective 
than the QD dose (p<0.0001).1  In the placebo-dosed patients,  66% rated the effectiveness 
as either “fair”, “good”, or excellent.  This percentage was increased to 80% in the QD-
dosed patients and 86% in the BID-dosed patients.   
It was determined that the incidence and type of adverse events in the intervention 
groups were similar to those seen in placebo patients.  The incidence of adverse events was 
4.1% (BID) and 2.7% (QD) higher than the placebo group .  The most common adverse 
events were headache, nausea, dizziness, nasopharngitis, dysmenorrhea.  Overall, the study 
concluded that  Frovatriptan, given prophylactically for 6 days, reduced the incidence of 
MRMs.1 
The results of the two Mannix studies demonstrated, as per patient report, that the 
mean percentage of PMPs without MRM was higher in the Naratriptan group compared to 
the placebo group in those patients who treated at least one PMP as well as in those patients 
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who treated all four PMPs (p<0.05).  Of the patients who treated at least one PMP, the 
percentage of patients with no MRM in any of the four treated PMP was higher (p=0.006) in 
the Naratriptan group than in the placebo group in the second study only.  The percentage of 
patients with no MRM in at least 50% of PMPs was higher in the Naratriptan group as 
compared to the placebo ground in both studies (p<0.05).  To summarize these results, the 
Mannix trial displayed that Naratriptan prevented MRMs better than placebo.2 
At visit two, satisfaction ratings of the efficacy of the study drug were measured via 
a patient questionnaire.  At this visit, satisfaction in the Naratriptan-treated group was 
similar in comparison to the placebo group.  However, at visit 5, based on the Cochran 
Mantel-Haenszel test, significantly more Naratriptan-treated patients reported greater overall 
satisfaction with the medication compared to placebo-treated patients (p<0.05).2   
There were no significant adverse events reported in Mannix’s studies.  In study one, 
the adverse events of the placebo and Naratriptan groups were comparable.  In study two, 
the incidence of adverse events was slightly higher with Naratriptan as compared to placebo-
treated patients.  The adverse events were paresthesias (drug related), acute pulmonary 
edema (not drug-related), and vertigo (drug related), migraines (not drug-related) and 
gastritis (drug-related).  Overall, Mannix’s study concluded that Naratriptan 1 mg BID for 6 
days is effective and generally well tolerated for short term prevention of MRMs.2    
The results of Facchinetti’s study demonstrated that the oral formulation of 
Sumatriptan was 91% effective.  A relapse occurred in 52% of MRM cases when being 
treated with Sumatriptan.3 
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Table 2. Efficacy of Triptan drugs on preventing MRMs 
Study CER EER RRR ARR NNT p-value 
 EER-CER/CER EER-CER 1/ARR  
Silberstein 0.67 0.41 -0.39 -0.26 4 <0.05 
Mannix 0.76 0.60 -0.21 -0.16 6 <0.05 
RRR= Relative Risk Reduction; ARR= Absolute Risk Reduction; NNT= Numbers Needed to Treat;  CER= 
control event rate; EER= experimental event rate 
Table 2 displays the treatment effects of the studies. ARR shows the decrease in 
amount of MRMs in the Triptan group compared to the placebo group. RRR determines the 
effectiveness of Triptan therapy and also the likelihood of another MRM despite Triptan 
therapy.  NNT determines the number of patients that needed to be treated with Triptan 
therapy to prevent a bad outcome (i.e. MRM) from occurring.  In Facchinetti’s study, a p-
value was unable to be calculated.  Instead, a percent change from baseline was calculated to 
determine efficacy.  Significant pain relief was reported in 78% of attacks (98/123) treated 
with oral Sumatriptan.3 
Table 3. Safety of Triptan drugs in preventing MRMs 
Study CER EER RRI ARI NNH p-value 
   EER-CER/CER EER-CER 1/ARI  
Silberstein 0.402 0.443 0.102 0.041 24 p= 0.185 
Mannix 0.29 0.33 0.14 0.04 25 NR 
RRI= Relative Risk Increase; ARI=Absolute Risk Increase; NNH= numbers needed to harm; 
CER= control event rate; EER= experimental event rate  
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Table 3 displays the safety of Triptan drugs in the prophylaxis of MRMs.  RRI 
determines the safety of Triptan therapy and also the likelihood of experiencing an adverse 
event during Triptan therapy.  ARI shows the increase in amount of adverse events in the 
Triptan group compared to the placebo group.  NNH was calculated to determine the 
number of patients that needed to be treated with Triptan therapy to cause an adverse event; 
24-25 patients need to be treated to get one adverse event.     
Discussion 
The randomized controlled trials used for this study demonstrate that administration 
of Triptans during the PMP for the prevention of MRMs is effective in reducing the 
incidence of MRMs.  The studies did not prove whether or not Triptan drugs were safe for 
MRM prophylaxis; the only p-value that was able to be calculated was shown to be 
insignificant.  However, it can be argued that the benefit of short-term MRM prophylaxis 
versus long term chronic prophylaxis is that short-term prophylaxis is not only able to 
reduce the amount of time that the body is exposed to medication but also decrease the 
amount adverse events.   
The three trials that were chosen for this paper studied three different types of 
Triptan drugs: Frovatriptan, Sumatriptan, and Naratriptan.  Although each of these three 
drugs are in the same class, they vary in duration of action, side effect profile, effectiveness 
in relation to prevention of MRMs, etc.  
Timing of the dosing of the study medication in relation to the anticipated onset of 
MRM was seen to be a area of potential imprecision.  Since women have differing lengths of 
menstrual cycles, it is difficult to determine a fixed PMP that would accurately apply to 
every woman.  In Mannix’s study, the percentage of patients who reported a post-treatment 
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migraine was higher in patients who received Naratriptan compared to the placebo group.2  
What remains to be seen is whether the post-treatment migraines were delayed MRMs, 
MRMs occurring during PMP due to treatment not covering the entire PMP, or if the post-
treatment attacks were simply a non-MRM attack.2   
The Facchinetti study looked at Triptan drugs in the acute treatment of MRMs 
whereas the other two studies looked at prophylaxis of MRMs with Triptans.  The 
Silberstein and Mannix studies were interested in the incidence of MRMs as their primary 
outcome.  Since Facchinetti’s study looked at the treatment of MRMs instead of prophylaxis 
of MRMs, it was difficult to find a primary outcome that would parallel with the Silberstein 
and Mannix studies.  However, prevention of MRM incidence was able to measured by 
using “number of relapses” as a marker for incidence of MRMs.  The relapse rate used as a 
marker for incidence does not delineate between oral and per rectum routes of 
administration.  Indeed, this represents an area of debate.   
Only one patient reported a adverse event that caused a disruption in medication 
administration.  Adverse events include sensation of chest tightness, a lump in the throat and 
tachycardia but the paper does not state which adverse events correlated with the oral-dosed 
group and which correlated with the suppository-dosed group.  The paper also does not state 
which adverse event was due to the medication.3 
Additionally, in the Mannix study, “nearly 30% of patients in each study were 
receiving daily migraine prophylaxis.”2  Therefore, it is difficult to determine whether the 
results of the study were truly due to that treatment regimen itself or to the daily 
prophylactic treatment previously taken by the patient.  
Ponzio, Triptans & MRMs  11 
Triptans are in the class of 5-HT1 agonists.  Serious cardiac events have been seen 
with the use of Triptan drugs: coronary artery vasospasm, transient myocardial ischemia, 
atrial and ventricular arrhythmias, and myocardial infarction.5 These adverse effects are very 
rare.  In general, side effects are minor: paresthesias, fatigue, flushing, chest tightness 
drowsiness, dizziness, nausea, and sweating.5   
Triptans are contraindicated in patients who have a history of CAD, CVA/TIA, PVD, 
hemiplegic or basilar migraines, and IBD. Triptans may cause an increase in blood pressure 
and thus are contraindicated in patients with hypertension that is uncontrolled.  Specifically, 
Naratriptan is contraindicated in patients with renal or hepatic dysfunction and Sumatriptan 
is contraindicated in patients who have taken a MAO inhibitor two weeks before 
administration of Sumatriptan.5   
Sumatriptan taken during pregnancy does not appear to increase the risk of birth 
defects.  There is not enough data to make the same case for other Triptan drugs.  Breast 
feeding also does not appear to cause any adverse events in the infant.  However, the data 
that supports this claim is limited.6  
Conclusions    
Triptans were shown to be effective in the prophylaxis of MRMs.  The results of the 
trials showed a significant decrease in incidence of MRMs when Triptans were administered 
during the PMP.  The studies did not prove whether or not Triptan drugs were safe when used in 
the prevention of MRMs; only one p-value out of the three studies was calculated and it was 
found to be statistically insignificant. 
Further studies need to be conducted that compare Triptan dosing schedules, dosages, 
duration of treatment, and routes of administration.  Further trials are also warranted comparing  
drugs within the Triptan class and their efficacy in preventing MRMs.
 References 
 
 
1 Silberstein, S. D., Elkind, A. H., Schreiber, C., & Keywood, C. (2004). A 
randomized trial of frovatriptan for the intermittent prevention of menstrual 
migraine. Neurology, 63(2), 261-269. 
 
2 Mannix, L. K., Savani, N., Landy, S., Valade, D., Shackelford, S., Ames, M. H., 
& Jones, M. W. (2007). Efficacy and tolerability of naratriptan for short-term 
prevention of menstrually related migraine: Data from two randomized, double-
blind, placebo-controlled studies. Headache, 47(7), 1037-1049. 
doi:10.1111/j.1526-4610.2007.00855. 
 
3. Facchinetti, F., Allais, G., Nappi, R. E., Gabellari, I. C., Di Renzo, G. C., 
Genazzani, A. R., . . . Benedetto, C. (2010). Sumatriptan (50 mg tablets vs. 25 mg 
suppositories) in the acute treatment of menstrually related migraine and oral 
contraceptive-induced menstrual migraine: A pilot study. Gynecological 
Endocrinology : The Official Journal of the International Society of 
Gynecological Endocrinology, 26(10), 773-779. 
doi:10.3109/09513590.2010.487607 
4.  Hawkins K, Wang S, Rupnow M. Direct Cost Burden Among Insured US 
Employees With Migraine. Headache: The Journal Of Head & Face Pain [serial 
online]. April 2008;48(4):553-563. Available from: Academic Search Premier, 
Ipswich, MA. Accessed September 27, 2012. 
5. Sanders-Bush E, Hazelwood L. Chapter 13. 5-Hydroxytryptamine (Serotonin) and 
Dopamine. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & 
Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: 
McGraw-Hill; 2011. 
http://www.accessmedicine.com/content.aspx?aID=16662305. Accessed 
December 1, 2012. 
6 Duong, S., Bozzo, P., Nordeng, H., & Einarson, A. Safety of triptans for migraine 
headaches during pregnancy and breastfeeding. Canadian Family Physician, 
2010; 56:6.   http://www.cfp.ca/content/56/6/537.short.  Accessed November 23 
2011. 
 
 
